Immunotherapy with immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) or the programmed cell death protein ligand 1 (PD-L1) has become one of the most promising approaches in the treatment of advanced NSCLC [3,4]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.